KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference [Yahoo! Finance]
KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at Jones Trading. They now have a $30.00 price target on the stock.